Dupilumab Subcutaneous and Orphenadrine Extended-Release Tablets
Determining the interaction of Dupilumab Subcutaneous and Orphenadrine Extended-Release Tablets and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dupilumab
Brand name: Dupixent
Synonyms: Dupilumab
Generic Name: orphenadrine
Brand name: Norflex, Banflex, Orphenate, Flexoject, Flexon, Mio-Rel, Myolin, Orfro, Norflex Injectable, Antiflex
Synonyms: Orphenadrine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dupilumab Subcutaneous-Orphenadrine Injection
- Dupilumab Subcutaneous-Orphenadrine w/A.C.
- Dupilumab Subcutaneous-Orphenadrine, aspirin, and caffeine
- Dupilumab Subcutaneous-Orphenate
- Dupilumab Subcutaneous-Orphengesic
- Dupilumab Subcutaneous-Orphengesic Forte
- Orphenadrine Extended-Release Tablets-Dupixent
- Orphenadrine Extended-Release Tablets-Duplex T Topical
- Orphenadrine Extended-Release Tablets-Durachol
- Orphenadrine Extended-Release Tablets-Duraclon
- Orphenadrine Extended-Release Tablets-Duraclon injection
- Orphenadrine Extended-Release Tablets-Duraflu